Key result
Azithromycin carries cardiovascular risks that prompted FDA labeling changes advising against its use in patients with known risk factors like QT-interval prolongation or bradycardia.
FDA labeling changes advise against azithromycin use in patients with specific cardiovascular risk factors due to potential cardiovascular risks.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to restrict azithromycin in QT-risk patients; leaves open absolute event rates and alternatives.
Mosholder et al. (2013) studied this question. Azithromycin carries cardiovascular risks that prompted FDA labeling changes advising against its use in patients with known risk factors like QT-interval prolongation or bradycardia.